{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"The MTD of panobinostat was defined as the dose at which the continual reassessment method (CRM) estimated that 25% of patients were expected to experience DLTs. Stratum 1 consisted of recurrent or progressive diffuse intrinsic pontine glioma (DIPG) patients who were treated with the \"3 times/week, three weeks on, one week off\" schedule (1 course = 28 days).","groups":[{"description":"Recurrent/progressive DIPG patients who were treated with the \"3 times/week, three weeks on, one week off\" schedule.","id":"OG000","title":"Stratum 1"}],"paramType":"NUMBER","populationDescription":"Patients who were enrolled on stratum 1 and were evaluable for dose finding assessment were used to determine the MTD for stratum 1. Of 19 patients enrolled on stratum 1, 2 patients were not evaluable for dose finding assessment due to receiving less than required dose of study drug. The remaining 17 patients were used to determine the MTD for stratum I.","reportingStatus":"POSTED","timeFrame":"4 weeks","title":"Maximum Tolerated Dose (MTD) of Panobinostat in Stratum 1","type":"PRIMARY","unitOfMeasure":"mg/m^2/day"}